What does the evidence say about Omega-3 Supplementation?

The current Migaku evidence database contains 2 reusable source documents for Omega-3 Supplementation. This answer focuses on benefits, uncertainty, and practical interpretation. - Consequently, identifying modifiable risk factors to prevent or delay cognitive decline is of critical public health importance [,]. [Liao Zheng-Bin (2026); evidence level 4] - By elucidating these specific neurobiological pathways, we aim to provide clinical evidence that informs the debate regarding the role of omega-3 fatty acids supplementation in slowing cognitive decline. [Liao Zheng-Bin (2026); evidence level 4] - 29 30 31 This study employed three commonly used cognitive scales to assess longitudinal trajectories associated with omega-3 supplementation: the Mini-Mental State Examination (MMSE), the Alzheimer’s Disease Assessment Scale–Cognitive Subscale 13 (ADAS-Cog13), and the Clinical Dementia Rating–Sum of Boxes (CDR-SB). [Liao Zheng-Bin (2026); evidence level 4] - 1 2 3 4 5 6 7 8 9 10 11 12 13 14 in vivo Alzheimer’s disease (AD), the leading cause of dementia, imposes a growing global public health burden []. [Liao Zheng-Bin (2026); evidence level 4] - Maternal 12-HETE is associated with childhood asthma and the responses to prenatal omega-3 supplementation [Chen L (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.